Compared with the placebo in the trial, erlotinib prolonged the survival of patients with EGFR-wt NSCLC [12.4 vs 8.7 months, HR 0.65 (95% CI 0.48–0.87); p = 0.0041] [15, 16]. Here, EGFR is linked to non-small cell lung carcinoma.